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ABSTRACT
Background: Generic drugs play an important role in the delivery of healthcare services 
in Kenya because of their affordability and availability. The Pharmacy and Poisons 
Board (PPB) is the body mandated to regulate the manufacture and supply of all drugs 
in Kenya. Approximately 90% of all applications for registration of drugs in Kenya 
are for generic drugs; however, there are concerns about the quality of generic drugs 
supplied to patients in Kenya. 
Objective: The study aimed to investigate the perceptions and views of the regulatory 
pharmacists on the registration system for generic drugs in Kenya, and the role of the 
National Quality Control Laboratory (NQCL).
Design: A cross-sectional survey was designed to collect the views and perceptions of 
regulatory pharmacists on the system for the registration of generic drugs for human 
use in Kenya. 
Setting: The survey was conducted in the capital city of Kenya, Nairobi from January 
to February 2007.  Nairobi was selected because it has a high concentration of 
pharmaceutical manufacturers and distributors involved in drug registration.
Participants: The sample included regulatory pharmacists working in the registration 
departments of pharmaceutical companies dealing in generic drugs for human use. 
A sample of 40 participants was recruited for the survey and a response rate of 60% 
was targeted.
Results: Over half (55.6%) of the respondents reported satisfaction with the drug 
registration system while 33.3% were unsatisfied. The level of satisfaction did not seem 
to be associated with the length of time it takes to register a generic drug (p-value=0.74) 
or the gender of the respondent (p-value=0.94). The respondents had confidence in 
the analytical procedures carried out by NQCL but were less satisfied with its role in 
generic drug registration process. The respondents made a number of recommendations 
towards better drug registration mechanisms for generic drugs in Kenya.
Conclusion: The study suggests that although the drug registration procedures appear 
to be working, there is need for improvement.  One area in which the registration of 
generic drugs in Kenya can benefit is in the observation of the operation of what other 
countries have done to streamline their drug registration systems.
INTRODUCTION
Medicines have played a critical role in the 
management of various diseases and ailments for 
some considerable time.  It became clear that there was 
a need to regulate these medicines to verify the claims 
made on their quality, safety and effectiveness. It has 
been suggested that the history of drug regulation 
dates back to 120 BC (1). Over the years many societies 
were set up and developed pharmacopoeias and 
described lists of drugs, their preparation, uses and 
control of drug quality. It is thought that the earliest 
pharmacopoeia was the New compound Dispensatory 
of 1498 issued by the Florentine guild of physicians 
and pharmacists. The first London Pharmacopoeia was 
published in 1618 (2).
 The process of regulation was accelerated later 
after the occurrence of disasters which resulted from 
patients using drugs of poor quality, with harmful 
ingredients and/or which lacked in efficacy. Presently, 
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the World Health Organisation (WHO) estimates 
that between 10% and 30% of medicines on sale in 
developing countries are counterfeit (3). For the most 
part, patients are ignorant about the risks associated 
with use of medicines. Hence there is need for strong 
regulatory bodies to assess and control the quality of 
drugs dispensed to the public.
 Many countries have found the use of a drug 
registration system is appropriate as a vetting 
mechanism for drugs licensing. Through this, the 
quality, safety and efficacy of a drug are assessed and 
a decision made on whether it should be registered for 
use. The need for this regulation becomes even more 
urgent because of the increasing number of drugs 
available, the globalization of the pharmaceutical 
industry and the threat posed by the circulation of 
substandard, harmful and counterfeit drugs.
 However, it is only in the last two decades that the 
generic drug industry has experienced tremendous 
growth. This suggests that knowledge in this area is 
often lacking and many countries are still working 
out the best ways of regulating generic drugs. An 
examination of the literature reveals that few studies 
have been conducted on the registration of generic 
drugs and the ones that are available deal with specific 
elements of the drug registration process. In the period 
1998-1999, the WHO conducted a multi-country study 
involving 10 countries to assess their drug regulatory 
mechanisms which included an assessment of the 
drug registration system (4). These studies however 
did not involve Kenya. 
 One of the areas of concern in the registration of 
generic drugs in Kenya is the occurrence of frequent 
backlogs. From the early 1990s, Kenya received many 
applications especially for human generic drugs and 
there was a very large backlog of 12 months by the late 
1990s. This led to many complaints about delays from 
applicants. Another challenge that the PPB has faced 
are concerns about the openness of communication 
with clients and provision of adequate guidance 
information for applications. Other issues included 
the kind of additional information requested during 
the evaluation process and the quality of decisions 
made.
 Perhaps the most critical challenge is concern 
about the quality of generic drugs in the marketplace. 
This has negatively impacted on the promotion of 
generic prescribing and generic substitution. There 
are also questions regarding the presence of too many 
generic brands per active ingredient in the market. 
Hence it is suggested that there is a need to assess 
whether the evaluation of generic drug applications 
by the PPB is optimal.
 During the course of its work in assessing 
the quality of generic drugs, PPB may decide to 
recommend samples for analysis. Samples are usually 
sent to the NQCL which is a government laboratory 
set up in 1992 through an amendment to the Pharmacy 
and Poisons Act, Chapter 244 (5). The laboratory on 
behalf of the government carries out tests requested 
by PPB on drug products and medicinal substances 
to determine whether they comply with their quality 
specifications. However, delays have occurred at this 
stage due to the laboratory taking long to release 
certificates of analysis. There have also been questions 
about the criteria used to decide which drug products 
to analyse.
 There are still a number of gaps to be filled in 
the understanding of the registration system for 
generic drugs in Kenya. Approximately 90% of all 
applications for registration of drugs in Kenya are for 
generic drugs hence their quality, safety and efficacy 
has profound effects on the healthcare system.  This 
study was therefore conducted to identify the gaps 
in the registration of generic drugs in Kenya and 
suggest ways of improving it.
MATERIALS AND METHODS
Study design and setting: A cross-sectional survey 
was designed to collect the views and perceptions 
of regulatory pharmacists on the system for the 
registration of generic drugs for human use in Kenya. 
The survey was conducted in Nairobi, the capital city 
of Kenya.  Nairobi city was chosen because it has a 
high concentration of pharmaceutical manufacturers 
and distributors involved in drug registration.
Population, sample size and sampling: The population 
was composed of the agents of foreign-based and 
local pharmaceutical manufacturers based in Nairobi 
which register drugs for human use with the PPB. 
The list held by the Drug Registration Department of 
the PPB was used to find the population frame.  On 
applying the inclusion and exclusion criteria to the 
population frame the study recruited a sample of 40 
participants and the whole sample was selected to 
participate in the survey. A response rate of at least 60% 
was targeted.  The regulatory pharmacist employed 
by each of these companies was recruited for the 
survey. A regulatory pharmacist was considered as 
one who worked for a pharmaceutical company and 
was involved in the registration of drugs. 
Survey questionnaire: The survey questionnaire was 
developed in English and comprised of questions 
on various aspects of generic drug registration in 
Kenya and the role of NQCL.  The questionnaire was 
distributed to the participants and completed by self-
administration.  Follow-up was conducted to ensure 
the completed questionnaires were returned. 
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Data analysis: The survey data was cleaned and 
edited for errors before being entered and analysed 
using SPSS 12.0 software. Descriptive statistics were 
used to summarise the respondents’ characteristics 
and the key results.  Associations between variables 
were assessed using Pearson’s Chi-square test and 
a p-value of less than 0.05 was considered to be 
statistically significant. 
Ethical considerations: Before carrying out the survey, 
permission was obtained from the registrar of the PPB 
to access records and recruit participants.  For this 
study, informed consent was assumed to have been 
obtained when a participant agreed to voluntarily 
fill and return the questionnaire.  All data collected 
was anonymous.
RESULTS
Characteristic of the respondents: Table 1 summarises 
the characteristics of the respondents.  A total of 40 
participants were recruited for the survey of whom 
31 returned completed questionnaires (a response 
rate of 77.5%). However on checking the acceptance 
criteria and background, only 27 respondents met 
the inclusion criteria and were included in the 
data analysis. The non-responders did not have 
any significant difference from the responders 
and therefore are not expected to affect the results. 
Majority of the respondents (68%) fell within the age 
range 31 to 40 years. The number of years of experience 
in drug registration ranged from 1 year to 30 years 
with a mean of 9.3 years and a median of 7 years.
Table 1
Distribution of respondents by age and gender*
Age group (years) Males Females Total
 No. (%) No. (%) No. (%)
Below 30  3   12 3   12
31-40 7  28 4   16 11   44
41-50 6  24  6    24
Over 50 5  20  5    20
Total 18  72 7  28 25   100
*one person missing age and gender and one person missing gender only were excluded
Perceptions of respondents on the introduction of new 
policies and procedures: The views of the respondents on 
the development of various policies and procedures 
for generic drug registration are summarised in 
Table 2. Except for the introduction of annual retention 
fee procedure (30.8%), over half of the respondents 
supported the introduction of the various policies 
and procedures at PPB (range, 53.8% to 100%).
Table 2
Views on introduction of policies and procedures at PPB
Policies and procedures Support for introduction of 
 policies & procedures
 Yes No
 No. (%)  No.  (%) 
Introduction of a policy to limit number of generic drugs per active ingredient 16  59.3  11 40.7
Introduction of annual retention fee per product 8  30.8  18 69.2
GMP inspection of manufacturing facility prior to registration of drugs 23  85.2  4  14.8
Use of internal evaluators by the PPB 19  70.4  8  29.6 
Introduction of timeframe for evaluation of applications by the PPB 27  100  
Introduction of timeframe for responding to queries by applicants 23  85.2  4  14.8
Introduction of electronic submission of applications 23  85.2  4  14.8
Development  of web site for tracking status of applications by applicants 25  96.2  1   3.8 
Introduction of a policy on which classes of generics should be analysed 14  53.8  12 46.2 
Introduction of a policy on which generic drugs to undergo bioequivalence testing 19  76.0  6  24.0
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Level of satisfaction with certain policies and procedures: 
Table 3 summarises the level of satisfaction of 
respondents with drug registration procedures and 
Table 3
Responses to questions on policies and procedures of drug registration
 Very satisfied Satisfied Not sure Unsatisfied Very
     unsatisfied
 No.  (%) No.  (%) No.  (%) No.  (%)  No.  (%)
Level of satisfaction with drug 
registration guidelines 2  7.4 14  51.9 4  14.8 7  25.9 
Level of satisfaction with current 
of format of requesting for more
information using query letters  14  51.9 2  7.4 10  37.0 1  3.7
Level of satisfaction with 
information in the drug 
registration certificate 2  7.7 11  42 4  15.4 7  26.9 2  7.7
Level of satisfaction with quality 
of evaluation by the Committee 
on Drug Registration 1  3.8 18  69.2 3 11.5 4  15.4 
documents.  For all questions asked, more than half 
of the respondents reported that they were satisfied 
or very satisfied. 
Responses on registration requirements for generic 
drugs and biological products: Sixteen (59.3%) of 
the respondents suggested that the registration 
requirements for a generic drug should be made less 
stringent than those for a new drug compared to 11 
(40.7%) who thought the requirements should be the 
same. On the other hand, a significant proportion of 
the respondents 23 (88.5%) felt that the registration 
requirements of generic biological products and 
respondents were of the view that the harmonisation 
of drug registration requirements in East Africa was 
long overdue and needed to be speeded up.
Responses to questions on the content of the application: 
Table 4 summarises the responses to questions 
regarding the content of the application.  Respondents 
reported high levels of satisfaction (satisfied or very 
satisfied) with administrative sections (92.6%) and 
pharmaceutical sections (77.8%) of the drug registration 
dossier.  However, there was less satisfaction with the 
clinical sections of the registration dossier (reported 
satisfied or very satisfied = 48.1%).
Table 4
Responses to questions on the level of satisfaction with the format of the drug registration dossier
 Very satisfied Satisfied Not sure Unsatisfied Very unsatisfied
 No. (%) No. (%) No. (%) No. (%) 
Level of satisfaction with 
administrative sections (1-7) 8  29.6  17  63 1  3.7 1  3.7 
Level of satisfaction with 
pharmaceutical sections (8-16) 3  11.1 18  66.7  6  22.2 
Level of satisfaction with 
clinical sections (17-19) 2   7.4 11 40.7 1  3.7 9  33.3 4  14.8
vaccines should be more stringent than those of 
other generic drugs compared to three (11.5%) who 
thought they should be the same. The majority of the 
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The role of the National Quality Control Laboratory: The 
PPB often selects samples for analysis in the laboratory 
before registration. In the responses to a question on 
relevance of this pre-registration analysis, 18 (66.7%) 
of the respondents thought it was very relevant, five 
(18.5%) thought it was relevant, three (11.1%) were 
not sure and one (3.7%) thought it was irrelevant. The 
responses to the question on the method of analysis 
which the laboratory should use in analysing samples 
were varied and 12 (52.2%) of the respondents felt 
that the laboratory should use the method and 
specifications stated in the official pharmacopoeias, 
seven (30.4%) thought the laboratory should use 
the same method and specifications used by the 
manufacturer, three (13%) thought the laboratory 
should use the method that it has adopted, and one 
(4.3%) felt that the laboratory should use the method 
and specifications of the innovator company.  The data 
is shown in Table 5 which summarises the responses 
on who should provide reference standards to be 
used in the analysis and who should pick sample 
for analysis.
Table 5
Responses on questions on who should submit reference standards and pick of analytical samples
 Provision of reference standards to  Opinion on who should
 NQCL for analysis  pick samples for analysis
  No. (%) No. (%)
Applicant 4 16.0 6 25.0
PPB 8 32.0 9 37.5
Laboratory 13 52.0 9 37.5
The majority of the respondents had confidence in 
the validity and reliability of the analytical results of 
the NQCL in which four (14.8%) said they were very 
confident, 14 (51.9%) were confident, eight (29.6%) 
were unsure and one (3.7%) were not confident. 
 Less than half of the respondents were satisfied 
with the role of NQCL in generic drug registration 
although a significant proportion was also unsure. 
From the responses, 11 (40.7%) were satisfied, 10 
(37.0%) were unsure, four (14.8%) were unsatisfied 
while two (7.4%) were very unsatisfied. Hence 
opinion on the role of the laboratory in the generic 
drug registration process was divided and a large 
proportion of the respondents seemed to be unsure. 
Those who were unsatisfied felt that the laboratory 
should play a greater role in post-market surveillance 
of drugs.
 A similar scenario was repeated in their 
perceptions of the length of time it takes to analyse 
a drug at the NQCL whereas six (23.1%) of the 
respondents thought that it was satisfactory, nine 
(34.6%) were unsure, seven (26.9%) thought it was 
unsatisfactory while four (15.4%) thought it was very 
unsatisfactory. 
Satisfaction with the drug registration system: More than 
half of the respondents were satisfied with the current 
system of drug registration in Kenya whereby one 
(3.7%) were very satisfied, 14 (51.9%) were satisfied, two 
(7.4%) were unsure and nine (33.3%) were unsatisfied. 
On the perception of the length of time it takes to 
register a generic drug in Kenya, five (18.5%) felt it was 
too long, 14 (51.9%) felt that it was long, seven (25.9%) 
thought it was acceptable while one (3.7%) thought it 
was short. From these data, it appears that most of the 
respondents were not satisfied with how long it takes 
to register a generic drug in Kenya.
 There was no association between the level of 
satisfaction with the current system for the registration 
of generic drugs and the gender of the respondent 
(p-value=0.94), and the level of satisfaction and 
the perception of respondents on length of time to 
register a generic drug in Kenya (p-value =0.74). The 
levels of satisfaction by respondents’ gender and the 
respondents’ opinion on length of time to register a 
generic drug are shown on Table 6.
Table 6
Associations between level of satisfaction and the gender and perception of length of time to register a generic drug
 Level of satisfaction with current 
          system of drug registration 
  Satisfied Unsatisfied Chi-square P-value
Respondents gender Males 10 7 0.006 0.94
 Females 4 3  
Respondents opinion on length of
time to register a generic drug Satisfactory 5 3 0.109 0.74
 Unsatisfactory 10 8  
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The rating of the level of satisfaction with the 
registration system for generic drugs was banded 
as follows: Very satisfied and Satisfied were banded 
together as ‘Satisfied’ while Not Sure, Unsatisfied and 
Very Unsatisfied were banded together as ‘Unsatisfied’. 
For responses of opinion on how long it takes to 
register a generic drug in Kenya, Too long and Long 
were banded together as ‘Unsatisfied’ while Acceptable 
and Short were banded together as ‘Satisfied’. This 
banding was done to get 2 x 2 table for Chi-square 
test computations.
DISCUSSION
This study presents important findings on the 
perceptions and views of the regulatory pharmacists 
on the registration system for generic drugs in 
Kenya, and the role of the National Quality Control 
Laboratory (NQCL).  Although more than half of 
the respondents 15 (55.6%) were satisfied with the 
system of registration for generic drugs in Kenya, a 
significant proportion was also unsatisfied (33.3%). 
Most of the respondents wanted the requirements for 
the registration of generic drugs to be less stringent 
than for innovator drugs. One of the examples 
highlighted was the need to remove the requirement 
for submission of clinical studies for generic drugs. 
However, the majority of the respondents suggested 
that the registration requirements for generic 
biological products should be more stringent than 
for other generic drugs. These results therefore 
suggest that respondents would like a review of the 
information required to be included in the dossiers to 
meet the specific needs and circumstances of different 
applications.
 The respondents generally supported a critical 
review of the drug registration system so that it is 
more robust, efficient, transparent and effective. 
The majority of respondents thought that the pre-
registration analysis of samples was relevant. They 
however seemed to be unclear as to the role of NQCL in 
the registration of generic drugs but were nonetheless 
confident about the quality of their analyses.
 Many of the respondents pointed out that it is 
just not enough to have a good registration system. 
Support for the processes such as GMP inspections, 
post-registration surveillance and pharmacovigilance 
should also be in place to ensure that good quality, 
safe and efficacious drugs reach consumers. The 
respondents were concerned about accountability and 
transparency in the drug registration processes at the 
PPB. They suggested among other things the setting 
of target timeframes for the registration process, 
establishing tracking systems for applications, 
and providing applicants with an opportunity for 
consultation before an application is rejected.
 The respondents appear to have considered 
other factors apart from the length of time it takes to 
register a generic drug in Kenya in deciding on their 
level of satisfaction with the drug registration system. 
This may mean that there are many factors at play in 
the process of registration of a drug that need to be 
looked into to address concerns of applicants.  The 
survey therefore succeeded in revealing the views 
and perceptions of the regulatory pharmacists on the 
registration process for generic drugs which would 
be useful during a review of the system.
 On methodological issues the cross-sectional 
survey was considered appropriate for collecting 
information on the views and perceptions of those 
familiar with the drug registration system in Kenya. 
Only regulatory pharmacists were involved because 
of the technical nature of the questions and bearing in 
mind that the questionnaires were self-administered. 
The option was chosen to cut costs and save time. 
However, our study has a number of limitations. 
Firstly, the survey sample included only participants 
from Nairobi and therefore the results may not be 
generalisable nationally.  A future survey could 
widen the range of respondents to other groups and 
wider geographic area which would allow more 
robust comparisons to be carried out.  In addition, the 
cost implications and the impact of implementation 
of the recommendations made were not estimated 
in the study. Further research on costs is required 
before implementation to ensure sustainability in 
the long run.
This study found that the drug registration system 
is a critical element in the management of the 
drug supply in a country. Through this system, a 
country filters what medicines are allowed to reach 
its citizens. Hence ensuring the quality, safety and 
efficacy of generic drugs is critical to the success of 
the policy of the government of promoting generic 
procurement, prescribing and dispensing to improve 
access to essential medicines. Proper regulation of 
the registration process to provide assurance on the 
interchangeability of pharmaceutical equivalents 
should therefore be part of that strategy. Well thought-
out post-market surveillance and pharmacovigilance 
programmes should also be implemented. The 
respondents of this study found the system of generic 
drug registration fairly satisfactory but put forward 
many useful perspectives and recommendations that 
need further consideration. 
In conclusion, the respondents generally supported a 
critical review of the drug registration system to make 
it more robust, efficient, transparent and effective.  A 
number of recommendations can be made as a result 
of this work, including:
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(i) A review of the information required to be 
included in the dossiers submitted to meet the 
specific needs and circumstances of different 
applications would streamline the applications 
process.
(ii) There is need for applicants to demonstrate the 
quality, safety and efficacy of their products 
through the submission of validation data, 
pharmaceutical development study reports, 
drug master files, batch manufacturing records 
and biopharmaceutics study reports. This 
will ensure that applicants fully understand 
their products and have identified the 
critical formulation and manufacturing 
process parameters that impact on quality. 
Circumstances under which certain exemptions 
may be granted should be laid down in the 
regulations.
(iii) Post-registration surveillance of drugs needs 
to be strengthened so that their quality is not 
compromised in the market. There needs to be a 
mechanism for the detection and identification 
of unregistered, substandard and counterfeit 
drugs.
(iv) The role of the National Quality Control 
Laboratory needs to be strengthened to assist 
in ensuring the quality, safety and efficacy of 
drugs before and after registration.
(v) The PPB needs to be more transparent and 
accountable to the applicants. Modalities for 
making electronic submissions, setting up a 
computerised tracking system for applications 
and developing internal capacity of PPB to 
evaluate drug registration applications more 
rapidly should be explored. There is also need 
to have clear timeframes for the disposal of 
applications.
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